Elevate your skills and expertise in Benzodiazepine Tapering with our webinar series, based on the Joint Clinical Practice Guideline on Benzodiazepine Tapering. Participants will learn how to determine when the risks of continued BZD prescribing outweigh the benefits for a given patient, and how to safely taper the medication when indicated in various settings.

Webinar Series Topics

• Considerations for Benzodiazepine Tapering 
• Benzodiazepine Tapering for Older Adults
• Considerations for Tapering Benzodiazepines in Primary Care
• Addressing Benzodiazepine Tapering Challenges

The development of this Guideline was generously funded by grant U01FD007804 from the US Food and Drug Administration, US Department of Health and Human Services. The contents are those of the authors and do not necessarily represent the official views of nor an endorsement by the FDA and Department of Health and Human Services or the US Government. The funders had no decision-making role in designing and conducting the systematic reviews, data collection, analysis, and interpretation of the data or approval privilege on the recommendations. As requested, FDA officers provided nonbinding feedback and technical support to the guideline panel and methodological team. This article was peer reviewed before publication. These guidelines are intended to help inform clinical decision making by prescribers and patients. They are not intended to be used for the purposes of restricting, limiting, delaying, or denying coverage for or access to a prescription issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice.